Get started
Author

Caroline Ogilvie Michie

Observed names: C O Michie, C. Michie, C. O. Michie, C.O. Michie, CO Michie, Caroline Michie, Caroline O Michie, Caroline O. Michie, Michie, C, Michie, Caroline
Observed institutions: Queen's University Belfast, NHS Lothian, Royal Marsden NHS Foundation Trust, Institute of Cancer Research, University of Aberdeen, Western General Hospital, Beatson West of Scotland Cancer Centre, Aberdeen Royal Infirmary, Ninewells Hospital, Edinburgh Cancer Research, NHS Fife, Royal Marsden Hospital, Royal Victoria Hospital, North Middlesex University Hospital NHS Trust, North Middlesex Hospital, Institute of Genetics and Cancer, Medical Research Council, University of Edinburgh
ORCID: 0000-0001-9198-0224
Observed ORCID: 0000-0001-9198-0224
OpenAlex ID: A5037375613
Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: Primary Results From TROPION-Breast01
2024 · Aditya Bardia, Komal Jhaveri, et al. · Journal of Clinical Oncology · 203
PDF
Germline Mutation in BRCA1 or BRCA2 and Ten-Year Survival for Women Diagnosed with Epithelial Ovarian Cancer
2014 · Francisco J. Candido-dos-Reis, Honglin Song, et al. · Clinical Cancer Research · 162
Molecular subgroup of high-grade serous ovarian cancer (HGSOC) as a predictor of outcome following bevacizumab.
2014 · Charlie Gourley, Andrena McCavigan, et al. · Journal of Clinical Oncology · 119
Expression of glycolytic enzymes in ovarian cancers and evaluation of the glycolytic pathway as a strategy for ovarian cancer treatment
2018 · Chrysi Xintaropoulou, Carol Ward, et al. · BMC Cancer · 107
PDF
Does shear wave ultrasound independently predict axillary lymph node metastasis in women with invasive breast cancer?
2013 · Andrew Evans, Petra Rauchhaus, et al. · Breast Cancer Research and Treatment · 106
PDF
Increased Incidence of Visceral Metastases in Scottish Patients With BRCA1/2-Defective Ovarian Cancer: An Extension of the Ovarian BRCAness Phenotype
2010 · Charlie Gourley, Caroline O. Michie, et al. · Journal of Clinical Oncology · 89
Interim heterogeneity changes measured using entropy texture features on T2-weighted MRI at 3.0 T are associated with pathological response to neoadjuvant chemotherapy in primary breast cancer
2017 · Shelley Henderson, Colin Purdie, et al. · European Radiology · 65
PDF
BRCA1 is both a prognostic and predictive biomarker of response to chemotherapy in sporadic epithelial ovarian cancer
2011 · Judith E. Carser, Jennifer E. Quinn, et al. · Gynecologic Oncology · 64
Anterior Gradient-3: A novel biomarker for ovarian cancer that mediates cisplatin resistance in xenograft models
2012 · Terry A. Gray, Nicola J. MacLaine, et al. · Journal of Immunological Methods · 48
Real world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom
2024 · Daire Hanna, Sophie Merrick, et al. · British Journal of Cancer · 39
PDF
High EMSY expression defines a BRCA‐like subgroup of high‐grade serous ovarian carcinoma with prolonged survival and hypersensitivity to platinum
2019 · Robert L. Hollis, Michael Churchman, et al. · Cancer · 38
PDF
Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification
2022 · Robert L Hollis, Alison M Meynert, et al. · Clinical Cancer Research · 37
PDF
Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis
2021 · Karen A. Gelmon, Peter A. Fasching, et al. · European Journal of Cancer · 35
PDF
The frequency and severity of capecitabine-induced hypertriglyceridaemia in routine clinical practice: a prospective study
2010 · C O Michie, M Sakala, et al. · British Journal of Cancer · 31
PDF
Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY
2023 · Judith Balmaña, Peter A. Fasching, et al. · Breast Cancer Research and Treatment · 24
A phase I study of oral rucaparib in combination with carboplatin.
2013 · L Rhoda Molife, Patricia Roxburgh, et al. · Journal of Clinical Oncology · 18
Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trials
2017 · Angela George, Rebecca Kristeleit, et al. · European Journal of Cancer · 11
PDF
Final results of the phase I trial of niraparib (MK4827), a poly(ADP)ribose polymerase (PARP) inhibitor incorporating proof of concept biomarker studies and expansion cohorts involving BRCA1/2 mutation carriers, sporadic ovarian, and castration resistant prostate cancer (CRPC).
2013 · Caroline Ogilvie Michie, Shahneen Kaur Sandhu, et al. · Journal of Clinical Oncology · 10
An Association of Cancer Physicians’ strategy for improving services and outcomes for cancer patients
2016 · Richard Baird, Ian Banks, et al. · ecancermedicalscience · 9
PDF
A phase I pharmacokinetic study of PM00104 (Zalypsis®) administered as a 24-h intravenous infusion every 3 weeks in patients with advanced solid tumors
2013 · J. Capdevila, S. Clive, et al. · Cancer Chemotherapy and Pharmacology · 8
Establishing a molecular taxonomy for epithelial ovarian cancer (EOC) from 363 formalin-fixed paraffin embedded (FFPE) specimens.
2011 · C. Gourley, C. O. Michie, et al. · Journal of Clinical Oncology · 7
UK real-world evidence on pembrolizumab and neoadjuvant chemotherapy for early-stage triple-negative breast cancer
2026 · J. McKeon, E. Daniels, et al. · ESMO Real World Data and Digital Oncology · 6
PDF
Expert UK consensus on the definition of high risk of recurrence in HER2-negative early breast cancer: A modified Delphi panel
2023 · E.R. Copson, J.E. Abraham, et al. · The Breast · 5
PDF
BRCA1 protein expression as a predictor of outcome following chemotherapy in sporadic epithelial ovarian cancer (EOC)
2009 · J. E. Carser, J. E. Quinn, et al. · Journal of Clinical Oncology · 3
Improving Inclusivity, Equity, and Diversity in Oncology Clinical Trials: A European Perspective
2023 · Benjamin Langley, Sophie Talas, et al. · EMJ Oncology · 2
PDF
Works count: 73
Citation count: 1,251
H-index: 16
I10-index: 18
Year
Topic
Type